YmAbs Therapeutics (YMAB)
(Delayed Data from NSDQ)
$16.26 USD
-0.24 (-1.45%)
Updated Mar 28, 2024 04:00 PM ET
After-Market: $16.30 +0.04 (0.25%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
YMAB 16.26 -0.24(-1.45%)
Will YMAB be a Portfolio Killer in March?
Zacks Investment Research is releasing its prediction for YMAB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for YMAB
Wall Street Analysts Think YmAbs Therapeutics (YMAB) Could Surge 31.33%: Read This Before Placing a Bet
YmAbs Therapeutics (YMAB) Surges 8.2%: Is This an Indication of Further Gains?
YMAB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 31.41% Upside in Y-mAbs Therapeutics, Inc. (YMAB): Can the Stock Really Move This High?
Are You Looking for a Top Momentum Pick? Why Y-mAbs Therapeutics, Inc. (YMAB) is a Great Choice
Y-mAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Tops Revenue Estimates
Other News for YMAB
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
Y-Mabs Therapeutics CFO Resigns, Ensures Smooth Transition
Y-mAbs Therapeutics says CFO Kruse will resign from his role
Y-mAbs Therapeutics CFO Bo Kruse resigns
Y-mAbs Therapeutics price target raised by $1 at H.C. Wainwright, here's why